Zai Lab Elects to Discontinue Development of ZL-3101 (Fugan) for Atopic Dermatitis - SC Read more about Zai Lab Elects to Discontinue Development of ZL-3101 (Fugan) for Atopic Dermatitis - SC
Zai Lab Announces Presentations at the 21st Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) and the IASLC 19th World Conference on Lung Cancer (WCLC) - SC Read more about Zai Lab Announces Presentations at the 21st Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) and the IASLC 19th World Conference on Lung Cancer (WCLC) - SC
Zai Lab’s ZL-2306 (niraparib) Completes Pharmacokinetics (PK) Study in Chinese Ovarian Cancer Patients Showing Comparable Profile to non-Chinese Patients - SC Read more about Zai Lab’s ZL-2306 (niraparib) Completes Pharmacokinetics (PK) Study in Chinese Ovarian Cancer Patients Showing Comparable Profile to non-Chinese Patients - SC
Zai Lab Appoints Professor Kai-Xian Chen, Ph.D., to its Board of Directors - SC Read more about Zai Lab Appoints Professor Kai-Xian Chen, Ph.D., to its Board of Directors - SC
Zai Lab Announces Dosing of First Patient in Phase 3 China Registration Trial of ZL-2306 (niraparib) for First-Line Maintenance Therapy in Platinum Responsive Ovarian Cancer - SC Read more about Zai Lab Announces Dosing of First Patient in Phase 3 China Registration Trial of ZL-2306 (niraparib) for First-Line Maintenance Therapy in Platinum Responsive Ovarian Cancer - SC
Zai Lab and Crescendo Biologics Enter Exclusive Worldwide License Agreement for Innovative Protein Therapeutics for Inflammatory Indications - SC Read more about Zai Lab and Crescendo Biologics Enter Exclusive Worldwide License Agreement for Innovative Protein Therapeutics for Inflammatory Indications - SC
Zai Lab Announces Presentations at June Investor Conferences - SC Read more about Zai Lab Announces Presentations at June Investor Conferences - SC
Zai Lab Announces Early Completion of Enrollment for ZL-2306 PK Study - SC Read more about Zai Lab Announces Early Completion of Enrollment for ZL-2306 PK Study - SC
Five Prime与再鼎医药宣布达成FGFR2b抗体FPA144在大中华地区的独占许可及全球战略开发合作协议 Read more about Five Prime与再鼎医药宣布达成FGFR2b抗体FPA144在大中华地区的独占许可及全球战略开发合作协议